Mouse pulmonary interstitial macrophages mediate the pro-tumorigenic effects of IL-9.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35778404.
- Also identified by DOI 10.1038/s41467-022-31596-7 and PMC identifier 9249769.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Although IL-9 has potent anti-tumor activity in adoptive cell transfer therapy, some models suggest that it can promote tumor growth. Here, we show that IL-9 signaling is associated with poor outcomes in patients with various forms of lung cancer, and is required for lung tumor growth in multiple mouse models. CD4<sup>+</sup> T cell-derived IL-9 promotes the expansion of both CD11c<sup>+</sup> and CD11c<sup>-</sup> interstitial macrophage populations in lung tumor models. Mechanistically, the IL-9/macrophage axis requires arginase 1 (Arg1) to mediate tumor growth. Indeed, adoptive transfer of Arg1<sup>+</sup> but not Arg1<sup>-</sup> lung macrophages to Il9r<sup>-/-</sup> mice promotes tumor growth. Moreover, targeting IL-9 signaling using macrophage-specific nanoparticles restricts lung tumor growth in mice. Lastly, elevated expression of IL-9R and Arg1 in tumor lesions is associated with poor prognosis in lung cancer patients. Thus, our study suggests the IL-9/macrophage/Arg1 axis is a potential therapeutic target for lung cancer therapy.
Medical subject headings
- Interleukin-9
- Lung Neoplasms
- Macrophages